STA
ABBV icon

Summit Trail Advisors’s AbbVie ABBV Stock Holding History

Summit Trail Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
66,840
+2,258
+3% +$486K 0.21% 67
2026
Q1 		$14M Buy
64,582
+16,124
+33% +$3.58M 0.2% 61
2025
Q4 		$11.1M Sell
48,458
-435
-0.9% -$99.1K 0.19% 71
2025
Q3 		$11.3M Buy
48,893
+5,855
+14% +$1.19M 0.16% 78
2025
Q2 		$7.99M Buy
43,038
+7,018
+19% +$1.3M 0.14% 86
2025
Q1 		$7.55M Buy
36,020
+6,544
+22% +$1.27M 0.25% 42
2024
Q4 		$5.24M Buy
29,476
+5,053
+21% +$929K 0.19% 42
2024
Q3 		$4.82M Buy
24,423
+3,865
+19% +$721K 0.12% 81
2024
Q2 		$3.53M Buy
20,558
+2,924
+17% +$484K 0.09% 94
2024
Q1 		$3.21M Sell
17,634
-2,608
-13% -$449K 0.09% 90
2023
Q4 		$3.14M Buy
20,242
+920
+5% +$134K 0.1% 72
2023
Q3 		$2.88M Buy
19,322
+1,801
+10% +$264K 0.11% 78
2023
Q2 		$2.36M Buy
17,521
+10,856
+163% +$1.59M 0.09% 93
2023
Q1 		$1.06M Buy
6,665
+400
+6% +$61.2K 0.04% 122
2022
Q4 		$1.01M Buy
6,265
+402
+7% +$61.6K 0.05% 116
2022
Q3 		$787K Buy
5,863
+2,719
+86% +$390K 0.04% 125
2022
Q2 		$482K Sell
3,144
-17
-0.5% -$2.6K 0.03% 194
2022
Q1 		$512K Buy
3,161
+715
+29% +$104K 0.04% 168
2021
Q4 		$331K Buy
2,446
+43
+2% +$5.08K 0.02% 214
2021
Q3 		$259K Buy
+2,403
New +$275K 0.02% 220
2020
Q4 		– Sell
-3,584
Closed -$354K – 187
2020
Q3 		$354K Buy
+3,584
New +$337K 0.07% 132
2019
Q1 		– Sell
-3,497
Closed -$322K – 84
2018
Q4 		$322K Sell
3,497
-3,724
-52% -$327K 0.11% 76
2018
Q3 		$683K Buy
7,221
+3,497
+94% +$332K 0.15% 81
2018
Q2 		$345K Sell
3,724
-8,084
-68% -$790K 0.12% 97
2018
Q1 		$997K Sell
11,808
-1,081
-8% -$119K 0.17% 135
2017
Q4 		$1.33M Buy
+12,889
New +$1.21M 0.17% 121

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Summit Trail Advisors's ABBV Position: Q2 2026 in Review

Summit Trail Advisors increased its AbbVie (ABBV) stake by 3.5% in Q2 2026, buying an estimated $486K and bringing the position to 66,840 shares worth $16.8M. The position accounts for 0.21% of the portfolio, ranked #67.

Summit Trail Advisors first reported a position in ABBV in Q4 2017 and has held it in 26 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Summit Trail Advisors held 66,840 shares of AbbVie worth $16.8M as of Q2 2026.
  • Summit Trail Advisors bought 2,258 AbbVie shares in Q2 2026, an estimated $486K.
  • AbbVie made up 0.21% of Summit Trail Advisors's portfolio in Q2 2026, its #67 holding.
  • Summit Trail Advisors first reported a position in AbbVie in Q4 2017 and has held it in 26 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.